The clinical usefulness of peritoneal dialysis fluids with neural pH and low glucose degradation product concentration: An open randomized prospective trial

Peritoneal Dialysis International

Volumn 28, Issue 2, 2008, Pages 174-182

  Choi, Hoon Young ^a   Kim, Dong Ki ^a   Lee, Tae Hee ^a   Moon, Sung Jin ^a   Han, Seung Hyeok ^a   Lee, Jung Eun ^a   Kim, Beom Seok ^a   Park, Hyeong Cheon ^a   Choi, Kyu Hun ^a   Ha, Sung Kyu ^a   Han, Dae Suk ^a   Lee, Ho Yung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Biocompatibility; CA125; Glucose degradation products; Neutral pH; Peritoneal function

Indexed keywords

CA 125 ANTIGEN; CREATINE; GLUCOSE DEGRADATION PRODUCT; PERITONEAL DIALYSIS FLUID; UREA;

ADULT; AGED; ANURIA; ARTICLE; BIOCOMPATIBILITY; CLINICAL TRIAL; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE CLEARANCE; DIALYSATE LEVEL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEMBRANE STRUCTURE; PERITONEAL FLUID LEVEL; PH; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; ULTRAFILTRATION; URINE VOLUME;

EID: 42349109993     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080802800214     Document Type: Article

References (37)

1. Jager KJ, Merkus MP, Dekker FW, Boeschoten EW, Tijssen JG, Stevens P, et al. Mortality and technique failure in patients starting chronic peritoneal dialysis: results of the Netherlands Cooperative Study on the Adequacy of Dialysis. NECOSAD Study Group. Kidney Int 1999; 55:1476-85.
2. Suzuki T, Kanno Y, Nakamoto H, Okada H, Sugahara S, Suzuki H. Peritoneal dialysis versus hemodialysis: a five-year comparison of survival and effects on the cardiovascular system, erythropoiesis, and calcium metabolism. Adv Perit Dial 2003; 19:148-54.
3. Korevaar JC, Feith GW, Dekker FW, van Manen JG, Boeschoten EW, Bossuyt PM, et al; NECOSAD Study Group. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003; 64:2222-8.
4. Schaubel DE, Blake PG, Fenton SSA. Trends in CAPD technique failure: Canada, 1981-1997. Perit Dial Int 2001; 21: 365-71.
5. Nakamoto H, Kawaguchi Y, Suzuki H. Is technique survival on peritoneal dialysis better in Japan? Perit Dial Int 2006; 26:136-43.
6. Heimbürger O, Waniewski J, Werynski A, Tranaeus A, Lindholm B. Peritoneal transport in CAPD patients with permanent loss of ultrafiltration capacity. Kidney Int 1990; 38:495-506.
7. Heimburger O, Wang T, Lindholm B. Alterations in water and solute transport with time on peritoneal dialysis. Perit Dial Int 1999; 19 (Suppl 2):S83-90.
8. Struijk DG, Krediet RT, Koomen GC, Hoek FJ, Boeschoten EW, vd Reijden HJ, et al. Functional characteristics of the peritoneal membrane in long-term continuous ambulatory peritoneal dialysis. Nephron 1991; 59:213-20.
9. Struijk DG, Krediet RT, Koomen GCM, Boeschoten EW, Hoek FJ, Arisz L. A prospective study of peritoneal transport in CAPD patients. Kidney Int 1994; 45:1739-44.
10. Davies SJ, Bryan J, Phillips L, Russell GI. Longitudinal changes in peritoneal kinetics: the effects of peritoneal dialysis and peritonitis. Nephrol Dial Transplant 1996; 11: 498-506.
11. Davies SJ, Phillips L, Griffiths AM, Russell LH, Naish PF, Russell GI. What really happens to people on long-term peritoneal dialysis? Kidney Int 1998; 54:2207-17.
12. Davies SJ, Philips L, Naish PF, Russell GI. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol 2001; 12:1046-51.
13. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, et al.; Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13:470-9.
14. Williams JD, Craig KJ, von Ruhland C, Topley N, Williams GT; Biopsy Registry Study Group. The natural course of peritoneal membrane biology during peritoneal dialysis. Kidney Int Suppl 2003; 88:S43-9.
15. Honda K, Nitta K, Horita S, Yumura W, Nihei H, Nagai R, et al. Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultrafiltration. Nephrol Dial Transplant 1999; 14:1541-9.
16. Tauer A, Knerr T, Niwa T, Schaub TP, Lage C, Passlick-Deetjen J, et al. In vitro formation of N(epsilon)-(carboxymethyl)lysine and imidazotones under conditions similar to continuous ambulatory peritoneal dialysis. Biochem Biophys Res Commun 2001; 280:1408-14.
17. Tauer A, Zhang X, Schaub TP, Zimmeck T, Niwa T, Passlick-Deetjen J, et al. Formation of advanced glycation end products during CAPD. Am J Kidney Dis 2003; 41(Suppl 1): S57-60.
18. Zeier M, Schwenger V, Deppisch R, Haug U, Weigel K, Bahner U, et al. Glucose degradation products in PD fluids: do they disappear from the peritoneal cavity and enter the systemic circulation? Kidney Int 2003; 63:298-305.
19. Morgan LW, Wieslander A, Davies M, Horiuchi T, Ohta Y, Beavis MJ, et al. Glucose degradation products (GDP) retard remesothelialization independently of D-glucose concentration. Kidney Int 2003; 64:1854-66.
20. Schwenger V, Morath C, Salava A, Amann K, Seregin Y, Deppisch R, et al. Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 2006; 17:199-207.
21. Mortier S, Faict D, Schalkwijk CG, Lameire NH, De Vriese AS. Long-term exposure to new peritoneal dialysis solutions: effects on the peritoneal membrane. Kidney Int 2004; 66:1257-65.
22. Lee HY, Park HC, Seo BJ, Do JY, Yun SR, Song HY, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25: 248-55.
23. Twardowski ZJ. Clinical value of standardized equilibration tests in CAPD patients. Blood Purif 1989; 7(2-3): 95-108.
24. Rippe B, Simonsen O, Heimburger O, Christensson A, Haraldsson B, Stelin G, et al. Long-term clinical effects of a peritoneal dialysis fluid with Less glucose degradation products. Kidney Int 2001; 59:348-57.
25. Rippe B, Wieslander A, Musi B. Long-term results with low glucose degradation product content in peritoneal dialysis fluids. Contrib Nephrol 2003; 140:47-55.
26. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, et al.; Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408-18.
27. Tranaeus A. A long-term study of a bicarbonate/lactate-based peritoneal dialysis solution-clinical benefits. The Bicarbonate/Lactate Study Group. Perit Dial Int 2000; 20: 516-23.
28. Visser CE, Brouwer-Steenbergen JJ, Betjes MG, Koomen GC, Beelen RH, Krediet RT. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients. Nephrol Dial Transplant 1995; 10:64-9.
29. Lai KN, Lai KB, Szeto CC, Ho KK, Poon P, Lam CW, et al. Dialysate cell population and cancer antigen 125 in stable continuous ambulatory peritoneal dialysis patients: their relationship with transport parameters. Am J Kidney Dis 1997; 29:699-705.
30. Ho-dac-Pannekeet MM, Hiralall JK, Struijk DG, Krediet RT. Longitudinal fodow-up of CA125 in peritoneal effluent. Kidney Int 1997; 51:888-93.
31. Okada T, Nakao T, Matsumoto H. Dialysate CA125 levels in stable peritoneal dialysis patients. Clin Nephrol 1999; 51: 65-6.
32. Jones S, Holmes CJ, Krediet RT, Mackenzie R, Faict D, Tranaeus A, et al.; Bicarbonate/Lactate Study Group. Bicarbonate/Lactate-based peritoneal dialysis solution increases cancer antigen 125 and decreases hyaluronic acid levels. Kidney Int 2001; 59:1529-38.
33. Fussholler A, Grabensee B, Plum J. Effluent CA 125 concentration in chronic peritoneal dialysis patients: influence of PD duration, peritoneal transport and PD regimen. Kidney Blood Press Res 2003; 26:118-22.
34. Hjelle JT, Miller-Hjelle MA, Dobbie JW. The biology of the mesothelium during peritoneal dialysis. Perit Dial Int 1995; 15(7 SuppQ:S13-22.
35. Jorres A. PD: a biological membrane and a non-biological fluid. Contrib Nephrol 2003; 140:1-9.
36. Cooker LA, Luneburg P, Holmes CJ, Jones S, Topley N; Bicarbonate/Lactate Study Group. Interleukin-6 levels decrease in effluent from patients dialyzed with bicarbonate/lactate-based peritonealdialysis solutions. Perit Dial Int 2001; 21 (Suppl 3):5102-7.
37. Fusshoeller A, Plail M, Grabensee B, Plum J. Biocompatibility pattern of a bicarbonate/lactate-buffered peritoneal dialysis fluid in APD: a prospective, randomized study. Nephrol Dial Transplant 2004; 19:2101-6.